翻訳と辞書 |
Betalutin Betalutin is an experimental pharmaceutical under clinical evaluation to treat primarily patients with B-cell non-Hodgkin lymphoma (NHL). It is intended for CD37 expressing non-Hodgkin lymphoma. According to the US National Cancer Institute 69 000 will be diagnosed with non-Hodgkin lymphoma and 19 000 will die from it in 2013. == Non-Hodgkin Lymphoma patients who no longer respond to treatment ==
Betalutin binds to another antigen on the cancer cells than the pharmaceuticals in use. It is assumed to be efficient when current treatment fails. Betalutin carries a short-lived radioactive betaemitter that kills the targeted cancer cell and cells close by in tumors by a cross-fire effect. Preclinical data indicate strong antitumor activity in CD37 expressing cells. CD37 was expressed in almost all B-cell non-Hodgkin Lymphoma samples tested by Dahle at al. () The first patient with non-Hodgkin lymphoma was included in a clinical trial at the Oslo University Hospital in Q4 2012. PET scans indicate that multiple tumors where no longer present after 3 months. The patient is alive as Betalutin was designated Orphan Drug status in the US in 2014 Q2.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Betalutin」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|